论文部分内容阅读
本文选用无膜稳定作用的非选择性β受体阻滞剂Ｎａｄｏｌｏｌ作为降门脉高压药物，应用ＥＣＴ检测服药前后肝硬化患者的肝、心、肾的血流动力学指标。结果显示服药后通过β受体的阻滞，降低了心率、心排血量与心搏指数，增加了每搏量与每搏指数；增加肾有效血浆流量与肾小球滤过率；轻度降低肝血流量，明显提高门脉灌流指数，提示关闭肝内动脉－门静脉短路等综合因素有力地控制了门脉高压、改善了肝脏功能，预防上消化道出血。
In this paper, Nadolol, a non-selective β-blocker without membrane-stabilizing effect, was used as the antihypertensive agent for portal hypertension. The hemodynamic parameters of liver, heart and kidney in patients with cirrhosis before and after treatment were detected by ECT. The results showed that after taking the drug, the block of β receptor reduced heart rate, cardiac output and heart rate index, increased stroke volume and stroke index; increased effective renal plasma flow and glomerular filtration rate; mild Reduce hepatic blood flow, significantly improve portal perfusion index, suggesting that the closure of intrahepatic arterial - portal vein short circuit and other comprehensive control of portal hypertension, improve liver function, prevention of upper gastrointestinal bleeding.